

## MAKING A MEANINGFUL IMPACT IN THE FIGHT AGAINST PEDIATRIC CANCER



## TMF'S MISSION

*We are dedicated to supporting research for the development of safer, more effective therapies for pediatric cancer patients.*

Since the cure of our son, Bodhi, from high-risk neuroblastoma in 2018, we have dedicated our efforts and funding toward Dr. Jacqueline Kraveka's research efforts.

## WHY YOUR DONATION IS IMPORTANT

- 100% of our fundraising goes to Dr. Kraveka's pediatric cancer research that is conducted at The Medical University of South Carolina.
- "Neuroblastoma is one of the most aggressive pediatric tumors that we see. It's one of the most common solid tumors we see but also has one of the worst prognoses. About half of children who are diagnosed with this tumor have high-risk neuroblastoma, and survival is only about 50%," -Dr. Kraveka
- MUSC is ranked as a "best hospital" for pediatric cancer for the 3rd consecutive year by U.S. News & World Report
- MUSC offers unique clinical trial opportunities through the Children's Oncology Group, the Pediatric Blood Marrow Transplant Consortium, Beat Childhood Cancer and others.
- Most chemotherapy treatment options for children today were founded in the 1950's. TMF provides funding for better treatments and advancement in treatments.



**"THIS IS THE FIRST DRUG APPROVED TO PREVENT RELAPSE FOR A PEDIATRIC CANCER PATIENT. IT GIVES NEW HOPE FOR OUR PATIENTS."**

**-DR. JACQUELINE KRAVEKA, D.O.**

- TMF funds research led by Dr. Kraveka, a national leader in neuroblastoma and an integral part of the executive committee and scientific committee for the Beat Childhood Cancer Research Consortium.
- In December 2023 The FDA approved of a drug, IWILFIN, to prevent relapse in high-risk neuroblastoma patients. Dr. Kraveka was the institutional principal investigator for the IWILFIN trials.
- The study demonstrated that the addition of IWILFIN improved survival in children with high-risk neuroblastoma.
- 84% of patients had no relapse by four years after immunotherapy in clinical trials when IWILFIN was used.



## CONTACT TMF

The McConnell Foundation is a 501(c)(3).  
All donations are tax deductible.



[www.themcconnellfoundation.com](http://www.themcconnellfoundation.com)



[hope@themcconnellfoundation.com](mailto:hope@themcconnellfoundation.com)